Semaglutide & GLP-1 Medications: What You Need to Know

GLP-1 (glucagon-like peptide-1) receptor agonists work by mimicking a hormone your gut naturally releases after eating. They produce several effects simultaneously:

Appetite suppression — GLP-1 acts on receptors in the brain's hypothalamus to reduce hunger signals and increase feelings of satiety. Many patients describe simply feeling full faster and thinking about food less.

Slowed gastric emptying — Food moves more slowly from the stomach to the small intestine, prolonging fullness and reducing post-meal blood sugar spikes.

Insulin regulation — These medications improve insulin sensitivity and help regulate blood sugar, making them effective for both weight loss and metabolic health.

Tirzepatide adds a second mechanism — GIP receptor agonism — and in trials has shown even greater weight loss than semaglutide alone, with some patients losing 20–25% of body weight.

Semaglutide is the active ingredient in two FDA-approved brand-name medications manufactured by Novo Nordisk:

Ozempic® — Approved by the FDA in 2017 for type 2 diabetes management. Although it is not approved by the FDA specifically as a weight-loss medication, it is widely prescribed off-label for weight loss because the appetite-suppression and gastric-emptying effects produce significant weight loss in most patients.

Wegovy® — Approved by the FDA in 2021 specifically for chronic weight management in adults with obesity or overweight plus a weight-related condition. Wegovy® contains the same active ingredient as Ozempic® (semaglutide) but is dosed and packaged for weight management.

Both Ozempic® and Wegovy® are once-weekly injections, share the same mechanism of action, and produce comparable results when dosed equivalently. The main practical differences are which FDA indication applies, what insurance coverage looks like, and pharmacy availability.

Compounded semaglutide — what Peak Medical Wellness prescribes — contains the same active ingredient (semaglutide) prepared by a licensed United States compounding pharmacy. It is not the same product as Ozempic® or Wegovy®, is not FDA-approved as a finished branded medication, and is dispensed under a different regulatory pathway. Many patients choose compounded semaglutide because of cost and supply considerations; others prefer the brand-name versions when they're accessible. Both options share the same active ingredient, and your provider can help you decide which fits your situation.

GLP-1 medications are medically indicated for adults who meet certain criteria, though candidacy involves a full clinical evaluation:

• BMI ≥ 30, or BMI ≥ 27 with a weight-related health condition (type 2 diabetes, hypertension, sleep apnea, etc.)

• History of difficulty losing weight with lifestyle changes alone

• No personal or family history of medullary thyroid cancer or MEN2 syndrome

• Not currently pregnant or planning pregnancy

• No active pancreatitis

You don't need to be severely obese to benefit. Many patients are in the overweight range but carry metabolic risk or have been stuck at a weight plateau for years.

In the landmark STEP trials, patients on semaglutide lost an average of 14.9% of body weight over 68 weeks compared to 2.4% in the placebo group. Tirzepatide trials (SURMOUNT) showed average losses of 20–22%.

Real-world results vary based on starting weight, dose, adherence, and lifestyle factors. Most patients begin to see meaningful results within 4–8 weeks of reaching their maintenance dose.

Equally important is what happens beyond the scale: improvements in blood pressure, cholesterol, blood sugar, joint pain, sleep quality, and energy levels are commonly reported.

Weight loss is typically maintained as long as the medication is continued. If stopped, weight regain is common — which is why a supervised program that addresses nutrition and habits alongside medication produces better long-term outcomes.

The most common side effects are GI-related and occur primarily during dose escalation:

• Nausea (most common, typically mild to moderate and temporary)

• Vomiting or diarrhea

• Constipation

• Fatigue during early dose increases

These side effects are substantially reduced by starting at a low dose and increasing slowly. Most patients find they resolve within a few weeks of reaching a stable dose.

Protein intake is critical during GLP-1 therapy. Rapid weight loss can include muscle mass loss if protein intake and resistance exercise are not prioritized. Our programs address this directly.

At Peak Medical Wellness, your provider monitors your progress at regular intervals, adjusts dosing based on your response, and helps you navigate side effects so you can stay the course.